OraSure Technologies Signs Agreement with the Supply Chain Management System for Supply of OraQuick(R) HIV Test to PEPFAR Countr
26 Luglio 2007 - 12:00PM
Business Wire
OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral
fluid diagnostics, today announced the execution of an agreement
for the supply of its OraQuick� Rapid HIV-1/2 Antibody Test to the
Supply Chain Management System (�SCMS�). Created with funds from
the President�s Emergency Plan for AIDS Relief, or PEPFAR, SCMS
procures essential medicines, diagnostic tests and other supplies
for the prevention and treatment of HIV for distribution to
developing countries supported by PEPFAR. Under the terms of the
new agreement, SCMS may purchase the OraQuick� test for an initial
one-year period and an optional second year. �The execution of an
agreement with SCMS is an important development for several
reasons,� said Douglas A. Michels, President and CEO of OraSure
Technologies. �This agreement will allow PEPFAR countries to access
the efficiencies of the consolidated supply chain managed by SCMS
in order to obtain our OraQuick� test. In addition, this agreement
will provide a vehicle for expanding our efforts to make the
OraQuick� test more widely available internationally, and in
particular in developing countries supported by PEPFAR. We are
committed to working with SCMS and other international agencies to
make rapid HIV testing as widely available as possible around the
world.� PEPFAR is a five-year, $15 billion program established in
2003 by President Bush to combat HIV/AIDS on a global basis.
Through PEPFAR, the U.S. Government works with international,
national and local leaders to support a multi-faceted and
integrated approach to HIV prevention, treatment and patient care.
About OraSure Technologies OraSure Technologies develops,
manufactures and markets oral fluid specimen collection devices
using proprietary oral fluid technologies, diagnostic products
including immunoassays and other in vitro diagnostic tests, and
other medical devices. These products are sold in the United States
as well as internationally to various clinical laboratories,
hospitals, clinics, community-based organizations and other public
health organizations, distributors, government agencies,
physicians� offices, and commercial and industrial entities.
OraSure Technologies is the leading supplier of oral-fluid
collection devices and in vitro diagnostic assays to the
employment, criminal justice, drug treatment, life insurance and
public health markets for the detection of abused drugs and the
antibodies to HIV. For more information on the Company, please go
to www.orasure.com.
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Lug 2023 a Lug 2024